Pro-adherence complementary audiovisual educational intervention model for chronic myeloid leukemia patients treated with imatinib mesylate

Background Imatinib mesylate (IM) treatment adherence is a challenge, especially in an economic-social population neglected from developing countries. Objective To create a new complementary audiovisual educational intervention model to improve IM treatment adherence of CML patients. Methods Two adh...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2023-04, Vol.29 (3), p.521-528
Main Authors: Barbosa, Adriana do Prado, Rodrigues Martins, Marcelo, Dewulf, Nathalie de Lourdes Souza, Carneiro, Wilsione José, Oliveira, Flávia Neri Meira de, Lemes, Guilherme Andrade, Cunha, Marianna Medeiros Barros da, Cruz, Alessandro de Carvalho, Cunha, Luiz Carlos da
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
BCR-ABL protein
Chronic myeloid leukemia
Developing countries
Female
Fusion protein
Humans
Imatinib
Imatinib Mesylate - therapeutic use
Inhibitor drugs
Intervention
LDCs
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Middle Aged
Myeloid leukemia
Patients
Sensory integration
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Imatinib mesylate (IM) treatment adherence is a challenge, especially in an economic-social population neglected from developing countries. Objective To create a new complementary audiovisual educational intervention model to improve IM treatment adherence of CML patients. Methods Two adherence verification methods were applied before and after intervention: modified Morisky-Green test and molecular responses (BCR-ABL transcripts quantification). Adherence estimates were calculated using univariate and multivariate component analysis (MCA) for the socio-demographic and clinical characteristics of patients. Results Modified Morisky-Green test results demonstrated a substantial increase of CML patient adherence from 23% (pre-film) to 65% (post-film). Greater improvement was obtained for patients presenting major molecular response (MMR) from 38% (pre-film) to 60% (post-film). Although slight gain for complete molecular response (CMR) from 23% (pre-film) to 26% (post-film) was achieved, it represents a total tumour regression. MCA identified that females
ISSN:1078-1552
1477-092X
DOI:10.1177/10781552211073894